# A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects

> **NCT02094937** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 430 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone Furoate/Vilanterol
- **DRUG:** Fluticasone Furoate 100 mcg
- **DRUG:** Fluticasone Propionate 250 mcg
- **DRUG:** Fluticasone Propionate 100 mcg
- **DRUG:** Fluticasone Furoate Placebo
- **DRUG:** Fluticasone Propionate Placebo

## Key facts

- **NCT ID:** NCT02094937
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-27
- **Primary completion:** 2015-08-28
- **Final completion:** 2015-08-28
- **Target enrollment:** 430 (ACTUAL)
- **Last updated:** 2017-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02094937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02094937, "A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02094937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*